查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2067639

非侵入性癌症診斷市場規模、佔有率和趨勢分析報告：按產品、技術、適應症和細分市場預測（2026-2033 年）

Non-invasive Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Pathology-based Instruments, Imaging Instruments), By Technology (Imaging, Liquid Biopsy, Immunoassay), By Indication, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

非侵入性癌症診斷市場概覽

全球非侵入性癌症診斷市場預計在 2025 年達到 808.7 億美元，預計到 2033 年將達到 1,390.9 億美元。

預計2026年至2033年間的複合年成長率將達到7.1%。這主要受癌症發病率上升、診斷技術進步以及公共和私營機構加強改善早期檢測和治療等因素所驅動。隨著癌症患者人數的持續成長，對高效、便捷且以患者為中心的診斷方法的需求也日益迫切。

早期發現對於改善治療效果和提高存活率至關重要。非侵入性診斷技術使醫護人員能夠對大規模人群篩檢，並在癌症早期發現癌症，而無需進行複雜且痛苦的手術。例如，根據世界衛生組織（WHO）和國際癌症研究機構（IARC）的數據，全球癌症負擔正在急劇增加。

2022年，全球通報新增癌症病例約2,000萬例，死亡病例約970萬例，確診五年內約有5,350萬人存活。預計2050年，新增癌症病例將超過3,500萬例，增幅高達77%。造成此現象的主要因素包括人口老化、人口成長、吸菸、飲酒、肥胖和空氣污染。因此，日益加重的癌症負擔推動了醫療保健系統對非侵入性診斷解決方案的需求不斷成長。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 非侵入性癌症診斷市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章 非侵入性癌症診斷市場：按產品分類的業務分析

  • 按產品分類的市場佔有率，2024 年和 2033 年
  • 市場規模、預測與趨勢分析：按產品分類，2021-2033 年
  • 裝置
  • 消耗品
  • 試劑盒和試劑

第5章 非侵入性癌症診斷市場：按技術分類的商業分析

  • 按技術分類的市場佔有率，2024 年和 2033 年
  • 市場規模、預測與趨勢分析：按技術分類，2021-2033 年
  • 影像
  • 液態切片
  • 免疫檢測

第6章 非侵入性癌症診斷市場：按適應症分類的業務分析

  • 按適應症分類的市場佔有率，2024 年和 2033 年
  • 市場規模、預測與趨勢分析：按適應症分類，2021-2033 年
  • 肺癌
  • 乳癌
  • 結腸癌
  • 攝護腺癌
  • 血癌
  • 肝癌
  • 子宮頸癌
  • 皮膚癌
  • 其他（甲狀腺癌等）

第7章 非侵入性癌症診斷市場：按最終用途分類的業務分析

  • 按最終用途分類的市場佔有率，2024 年和 2033 年
  • 市場規模、預測和趨勢分析：按最終用途分類，2021-2033 年
  • 醫院
  • 診斷實驗室
  • 其他（大學、研究機構等）

第8章 非侵入性癌症診斷市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲和紐西蘭
    • 韓國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第9章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Abbott Laboratories
    • GE HealthCare
    • Siemens Healthineers AG
    • Koninklijke Philips NV
    • Canon Medical Systems
    • F. Hoffmann-La Roche Ltd
    • Illumina, Inc
    • Guardant Health, Inc.
    • Thermo Fisher Scientific Inc.
    • FONAR Corporation
Product Code: GVR-4-68040-912-5

Non-invasive Cancer Diagnostics Market Summary

The global non-invasive cancer diagnostics market size was estimated at USD 80.87 billion in 2025 and is projected to reach USD 139.09 billion by 2033, growing at a CAGR of 7.1% from 2026 to 2033, due to the increasing prevalence of cancer, advancements in diagnostic technologies, and the growing initiatives undertaken by both public and private organizations to improve early detection and treatment. As the number of cancer cases continues to rise, there is a growing need for effective, accessible, and patient-friendly diagnostic methods.

Early detection plays a critical role in improving treatment outcomes and survival rates. Non-invasive diagnostic techniques enable healthcare providers to screen large populations and detect cancer at earlier stages without requiring complex or painful procedures. For example, according to the World Health Organization and the International Agency for Research on Cancer, the global burden of cancer is rising significantly.

In 2022, around 20 million new cancer cases and 9.7 million deaths were reported worldwide, with about 53.5 million people living within five years of a diagnosis. Cancer cases are expected to reach over 35 million by 2050, a 77% increase, mainly due to population aging, population growth, and risk factors such as tobacco use, alcohol consumption, obesity, and air pollution. As a result, the rising burden of cancer is increasing the demand for non-invasive diagnostic solutions across healthcare systems.

Global Non-Invasive Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global non-invasive cancer diagnostics market report based on product, technology, indication, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Instruments
    • Pathology-based Instruments
    • Polymerase Chain Reaction (PCR) Instruments
    • Next-generation Sequencing (NGS) Instruments
    • Microarrays
    • Imaging Instruments
    • Magnetic Resonance Imaging (MRI)
    • Computed Tomography (CT)
    • Positron Emission Tomography (PET)
    • Mammography
    • Others (Ultrasound, etc.)
  • Consumables
  • Kits & Reagents
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Imaging
  • Liquid Biopsy
  • Immunoassay
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Blood Cancer
  • Liver Cancer
  • Cervical Cancer
  • Skin Cancer
  • Others (Thyroid Cancer, etc.)
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic Laboratories
  • Others (Academic & Research Institutes, etc.)
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Technology
    • 1.2.3. Indication
    • 1.2.4. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Non-Invasive Cancer Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Non-Invasive Cancer Diagnostics Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Instruments
    • 4.4.1. Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Pathology-based Instruments
      • 4.4.2.1. Pathology-based Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.2. Polymerase Chain Reaction (PCR) Instruments
        • 4.4.2.2.1. Polymerase Chain Reaction (PCR) Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.3. Next-generation Sequencing (NGS) Instruments
        • 4.4.2.3.1. Next-generation Sequencing (NGS) Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.4. Microarrays
        • 4.4.2.4.1. Microarrays Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Imaging Instruments
      • 4.4.3.1. Imaging Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.2. Magnetic Resonance Imaging (MRI)
        • 4.4.3.2.1. Magnetic Resonance Imaging (MRI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.3. Computed Tomography (CT)
        • 4.4.3.3.1. Computed Tomography (CT) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.4. Positron Emission Tomography (PET)
        • 4.4.3.4.1. Positron Emission Tomography (PET) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.5. Mammography
        • 4.4.3.5.1. Mammography Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.6. Others (Ultrasound, etc.)
        • 4.4.3.6.1. Others (Ultrasound, etc.) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Consumables
    • 4.5.1. Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Kits & Reagents
    • 4.6.1. Kits & Reagents Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Non-Invasive Cancer Diagnostics Market: Technology Business Analysis

  • 5.1. Technology Market Share, 2024 & 2033
  • 5.2. Technology Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Technology, 2021 to 2033 (USD Million)
  • 5.4. Imaging
    • 5.4.1. Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Liquid Biopsy
    • 5.5.1. Liquid Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Immunoassay
    • 5.6.1. Immunoassay Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Non-Invasive Cancer Diagnostics Market: Indication Business Analysis

  • 6.1. Indication Market Share, 2024 & 2033
  • 6.2. Indication Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 6.4. Lung Cancer
    • 6.4.1. Lung Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Breast Cancer
    • 6.5.1. Breast Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Colorectal Cancer
    • 6.6.1. Colorectal Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Prostate Cancer
    • 6.7.1. Prostate Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Blood Cancer
    • 6.8.1. Blood Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Liver Cancer
    • 6.9.1. Liver Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.10. Cervical Cancer
    • 6.10.1. Cervical Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.11. Skin Cancer
    • 6.11.1. Skin Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.12. Others (Thyroid Cancer, etc.)
    • 6.12.1. Others (Thyroid Cancer, etc.) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Non-Invasive Cancer Diagnostics Market: End Use Business Analysis

  • 7.1. End Use Market Share, 2024 & 2033
  • 7.2. End Use Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 7.4. Hospitals
    • 7.4.1. Hospitals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Diagnostic Laboratories
    • 7.5.1. Diagnostic Laboratories Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Others (Academic & Research Institutes, etc.)
    • 7.6.1. Others (Academic & Research Institutes, etc.) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Non-Invasive Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Type Disease Prevalence
      • 8.4.2.3. Regulatory/ Reimbursement Framework
      • 8.4.2.4. U.S. Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Type Disease Prevalence
      • 8.4.3.3. Regulatory/ Reimbursement Framework
      • 8.4.3.4. Canada Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Type Disease Prevalence
      • 8.4.4.3. Regulatory/ Reimbursement Framework
      • 8.4.4.4. Mexico Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Type Disease Prevalence
      • 8.5.2.3. Regulatory/ Reimbursement Framework
      • 8.5.2.4. UK Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Type Disease Prevalence
      • 8.5.3.3. Regulatory/ Reimbursement Framework
      • 8.5.3.4. Germany Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Type Disease Prevalence
      • 8.5.4.3. Regulatory/ Reimbursement Framework
      • 8.5.4.4. France Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Type Disease Prevalence
      • 8.5.5.3. Regulatory/ Reimbursement Framework
      • 8.5.5.4. Italy Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Type Disease Prevalence
      • 8.5.6.3. Regulatory/ Reimbursement Framework
      • 8.5.6.4. Spain Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Type Disease Prevalence
      • 8.6.2.3. Regulatory/ Reimbursement Framework
      • 8.6.2.4. Japan Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Type Disease Prevalence
      • 8.6.3.3. Regulatory/ Reimbursement Framework
      • 8.6.3.4. China Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Type Disease Prevalence
      • 8.6.4.3. Regulatory/ Reimbursement Framework
      • 8.6.4.4. India Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia & New Zealand
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Type Disease Prevalence
      • 8.6.5.3. Regulatory/ Reimbursement Framework
      • 8.6.5.4. Australia Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Type Disease Prevalence
      • 8.6.6.3. Regulatory/ Reimbursement Framework
      • 8.6.6.4. South Korea Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Type Disease Prevalence
      • 8.7.2.3. Regulatory/ Reimbursement Framework
      • 8.7.2.4. Brazil Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Type Disease Prevalence
      • 8.7.3.3. Regulatory/ Reimbursement Framework
      • 8.7.3.4. Argentina Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Type Disease Prevalence
      • 8.8.2.3. Regulatory/ Reimbursement Framework
      • 8.8.2.4. South Africa Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Type Disease Prevalence
      • 8.8.3.3. Regulatory/ Reimbursement Framework
      • 8.8.3.4. Saudi Arabia Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Type Disease Prevalence
      • 8.8.4.3. Regulatory/ Reimbursement Framework
      • 8.8.4.4. UAE Non-Invasive Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Abbott Laboratories
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. GE HealthCare
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Siemens Healthineers AG
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Koninklijke Philips N.V.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Canon Medical Systems
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. F. Hoffmann-La Roche Ltd
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Illumina, Inc
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Guardant Health, Inc.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Thermo Fisher Scientific Inc.
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. FONAR Corporation
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Non-invasive cancer diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 5 Global Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 6 Global Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 7 Global Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 8 North America Non-invasive cancer diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 9 North America Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 10 North America Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 11 North America Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 12 North America Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 13 U.S Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 14 U.S Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 15 U.S Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 16 U.S Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 17 Canada Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 18 Canada Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 19 Canada Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 20 Canada Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 21 Mexico Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 22 Mexico Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 23 Mexico Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 24 Mexico Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 25 Europe Non-invasive cancer diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 26 Europe Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 27 Europe Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 28 Europe Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 29 Europe Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 30 UK Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 31 UK Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 32 UK Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 33 UK Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 34 Germany Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 35 Germany Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 36 Germany Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 37 Germany Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 38 France Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 39 France Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 40 France Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 41 France Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 42 Italy Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 43 Italy Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 44 Italy Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 45 Italy Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 46 Spain Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 47 Spain Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 48 Spain Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 49 Spain Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Non-invasive cancer diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 52 Asia Pacific Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 53 Asia Pacific Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 54 Asia Pacific Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 55 Japan Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 56 Japan Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 57 Japan Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 58 Japan Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 59 China Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 60 China Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 61 China Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 62 China Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 63 India Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 64 India Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 65 India Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 66 India Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 67 Australia & New Zealand Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 68 Australia & New Zealand Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 69 Australia & New Zealand Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 70 Australia & New Zealand Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 71 South Korea Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 72 South Korea Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 73 South Korea Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 74 South Korea Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 75 Latin America Non-invasive cancer diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 76 Latin America Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 77 Latin America Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 78 Latin America Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 79 Latin America Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 80 Brazil Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 81 Brazil Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 82 Brazil Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 83 Brazil Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 84 Argentina Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 85 Argentina Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 86 Argentina Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 87 Argentina Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 88 Middle East & Africa Non-invasive cancer diagnostics market, by country, 2021 - 2033 (USD Million)
  • Table 89 Middle East & Africa Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 90 Middle East & Africa Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 91 Middle East & Africa Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 92 Middle East & Africa Non-invasive cancer diagnostic market, by end use, 2021 - 2033 (USD Million)
  • Table 93 South Africa Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 94 South Africa Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 95 South Africa Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 96 South Africa Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 97 Saudi Arabia Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 98 Saudi Arabia Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 99 Saudi Arabia Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 100 Saudi Arabia Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 101 UAE Non-invasive cancer diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 102 UAE Non-invasive cancer diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 103 UAE Non-invasive cancer diagnostics market, by indication, 2021 - 2033 (USD Million)
  • Table 104 UAE Non-invasive cancer diagnostics market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Non-invasive cancer diagnostic market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Non-invasive cancer diagnostics market dynamics
  • Fig. 12 Non-invasive cancer diagnostics market: Porter's five forces analysis
  • Fig. 13 Non-invasive cancer diagnostics market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Million)
  • Fig. 15 Instruments market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 16 Pathology-based instruments market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 Polymerase Chain Reaction (PCR) Instruments market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 Next-generation Sequencing (NGS) Instruments market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 Microarrays market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 Imaging instruments market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Magnetic Resonance Imaging (MRI) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Computed Tomography (CT) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Positron Emission Tomography (PET) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Mammography market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Others (Ultrasound, etc.) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Consumables market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Kits & reagents market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Technology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Imaging market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Liquid biopsy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Immunoassay market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Indication market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Lung cancer market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Breast cancer market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Colorectal cancer market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Prostate market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Blood market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Liver market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Cervical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Skin market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Others (Thyroid Cancer, etc.) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 End use market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Hospitals market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Diagnostic laboratories market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Others (Academic & Research Institutes, etc.) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Non-invasive cancer diagnostic market revenue, by region
  • Fig. 47 Regional marketplace: Key takeaways
  • Fig. 48 North America Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 U.S. country dynamics
  • Fig. 50 U.S. Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Canada country dynamics
  • Fig. 52 Canada Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Mexico country dynamics
  • Fig. 54 Mexico Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Europe Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 UK country dynamics
  • Fig. 57 UK Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Germany country dynamics
  • Fig. 59 Germany Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 France country dynamics
  • Fig. 61 France Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Italy country dynamics
  • Fig. 63 Italy Non-invasive cancer diagnostic market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Spain country dynamics
  • Fig. 65 Spain Non-invasive cancer diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 66 Asia Pacific Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Japan country dynamics
  • Fig. 68 Japan Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 China country dynamics
  • Fig. 70 China Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 India country dynamics
  • Fig. 72 India Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Australia & New Zealand country dynamics
  • Fig. 74 Australia & New Zealand Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 South Korea country dynamics
  • Fig. 76 South Korea Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Latin America Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Brazil country dynamics
  • Fig. 79 Brazil Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Argentina country dynamics
  • Fig. 81 Argentina Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 MEA Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)s
  • Fig. 83 South Africa country dynamics
  • Fig. 84 South Africa Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 Saudi Arabia country dynamics
  • Fig. 86 Saudi Arabia Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 87 UAE country dynamics
  • Fig. 88 UAE Non-invasive cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 89 Company categorization
  • Fig. 90 Company market position analysis
  • Fig. 91 Strategic framework